Breaking News, Financial News

Bristol-Myers Squibb 1Q

Biopharmaceutical sales totaled $4.3 billion in the quarter, with U.S. sales up 13% to $2.8 billion and International sales down 11% to $1.5 billion (+2% excluding foreign exchange impact).

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bristol-Myers Squibb 1Q 1Q Revenues: $5.0 billion (+3%) 1Q Earnings: $638 million (-3.5%) Comments: Biopharmaceutical sales totaled $4.3 billion in the quarter, with U.S. sales up 13% to $2.8 billion and International sales down 11% to $1.5 billion (+2% excluding foreign exchange impact). Sales growth in the quarter was led by key drivers including Abilify, up 30% to $589 million, and Plavix, up 10% to $1.4 billion. Sales of Orencia grew 43% to $124 million and Sprycel sales were up 33%...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters